all

View the September 2019 NELA Board of Directors minutes by clicking here.

View the October 2019 Pacific quarterly e-newsletter by clicking here. 

The NLA has published a scientific statement on the use of icosapent ethyl (IPE) in statin-treated patients that is based on the results of REDUCE-IT, the cardiovascular outcomes trial that examined the effects of IPE on major adverse cardiovascular events in high or very high-risk statin-treated patients with elevated triglycerides.